Posters Overview
Trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, comprises of an anti-HER2 antibody, a cleavable linker, and a topoisomerase I inhibitor payload, and an enzymatically cleavable peptide-based linker. DS-8201 addresses the limitations of previous-generation ADCs. To learn the DS-8201 actual effect on the disease, the conjugated payload and total antibody in the body should be monitored. Therefore, it is necessary to establish a method for both of them. UPLC-MS/MS is a sensitive platform for peptide and payload analysis. It can be used to detect them simultaneously.
Complete the form to view and download this poster.
Stay Connected
Keep up with the latest news and insights.